{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:41:36Z","timestamp":1792798896938,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T00:00:00Z","timestamp":1589241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clinicopathological features and surgical outcomes of patients with fibrolamellar hepatocellular carcinoma (FL-HCC) are underreported. The aim of this study is to describe clinical characteristics and surgical outcomes for patients with this rare tumor to raise awareness among clinicians and surgeons.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective review of records of a tertiary referral center and specialized liver unit was performed. Out of 3623 patients who underwent liver resection, 366 patients received surgical treatment for HCC; of them, eight (2.2%) had FL-HCC and were resected between October 2001 and December 2018.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight patients (3 males and 5 females) with FL-HCC (median age 26\u2009years) underwent primary surgical treatment. All patients presented with unspecific symptoms or were diagnosed as incidental finding. No patient had cirrhosis or other underlying liver diseases. Coincidentally, three patients (37.5%) had a thromboembolic event prior to admission. The majority of patients had BCLC stage C and UICC stage IIIB\/IVA; four patients (50%) presented with lymph node metastases. The median follow-up period was 33.5\u2009months. The 1-year survival was 71.4%, and 3-year survival was 57.1%. Median survival was at 36.4\u2009months. Five patients (62.5%) developed recurrent disease after a median disease-free survival of 9\u2009months. Two patients (25.0%) received re-resection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>FL-HCC is a rare differential diagnosis of liver masses in young patients. Since the prognosis is limited, patients with incidental liver tumors or lesions with suspicious features in an otherwise healthy liver should be presented at a specialized hepatobiliary unit. Thromboembolism might be an early paraneoplastic symptom and needs to be elucidated further in the context of FL-HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12957-020-01855-2","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T12:33:15Z","timestamp":1589286795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Clinical features and surgical outcomes of fibrolamellar hepatocellular carcinoma: retrospective analysis of a single-center experience"],"prefix":"10.1186","volume":"18","author":[{"given":"Anastasia","family":"Lemekhova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hornuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Polychronidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Longerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Heinz","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"B\u00fcchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianeb","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,12]]},"reference":[{"issue":"2","key":"1855_CR1","first-page":"168","volume":"91","author":"HA Edmondson","year":"1956","unstructured":"Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91(2):168\u201386.","journal-title":"AMA J Dis Child."},{"issue":"5","key":"1855_CR2","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1177\/2050640613501507","volume":"1","author":"T Eggert","year":"2013","unstructured":"Eggert T, McGlynn KA, Duffy A, Manns MP, Greten TF, Altekruse SF. Fibrolamellar hepatocellular carcinoma in the USA, 2000-2010: a detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database. United European Gastroenterol J. 2013;1(5):351\u20137.","journal-title":"United European Gastroenterol J."},{"issue":"3","key":"1855_CR3","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/hep.20096","volume":"39","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798\u2013803.","journal-title":"Hepatology."},{"issue":"6","key":"1855_CR4","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.jamcollsurg.2012.08.001","volume":"215","author":"MN Mavros","year":"2012","unstructured":"Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012;215(6):820\u201330.","journal-title":"J Am Coll Surg."},{"issue":"1","key":"1855_CR5","first-page":"3","volume":"6","author":"CS Ang","year":"2013","unstructured":"Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointestinal cancer research : GCR. 2013;6(1):3\u20139.","journal-title":"Gastrointestinal cancer research : GCR."},{"issue":"2","key":"1855_CR6","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1002\/1097-0142(19800715)46:2<372::AID-CNCR2820460227>3.0.CO;2-S","volume":"46","author":"JR Craig","year":"1980","unstructured":"Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980;46(2):372\u20139.","journal-title":"Cancer."},{"issue":"2","key":"1855_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0168-8278(87)80580-9","volume":"5","author":"HJ Hodgson","year":"1987","unstructured":"Hodgson HJ. Fibrolamellar cancer of the liver. J Hepatol. 1987;5(2):241\u20137.","journal-title":"J Hepatol."},{"issue":"7","key":"1855_CR8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0046-8177(88)80261-2","volume":"19","author":"MA Berman","year":"1988","unstructured":"Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988;19(7):784\u201394.","journal-title":"Hum Pathol."},{"issue":"1","key":"1855_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40644-018-0143-y","volume":"18","author":"V Palm","year":"2018","unstructured":"Palm V, Sheng R, Mayer P, Weiss KH, Springfeld C, Mehrabi A, et al. Imaging features of fibrolamellar hepatocellular carcinoma in gadoxetic acid-enhanced MRI. Cancer Imaging. 2018;18(1):9.","journal-title":"Cancer Imaging."},{"issue":"4","key":"1855_CR10","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1002\/1097-0142(19820815)50:4<702::AID-CNCR2820500414>3.0.CO;2-F","volume":"50","author":"DC Farhi","year":"1982","unstructured":"Farhi DC, Shikes RH, Silverberg SG. Ultrastructure of fibrolamellar oncocytic hepatoma. Cancer. 1982;50(4):702\u20139.","journal-title":"Cancer."},{"issue":"8","key":"1855_CR11","first-page":"633","volume":"50","author":"M Imkie","year":"2005","unstructured":"Imkie M, Myers SA, Li Y, Fan F, Bennett TL, Forster J, et al. Fibrolamellar hepatocellular carcinoma arising in a background of focal nodular hyperplasia: a report of 2 cases. J Reprod Med. 2005;50(8):633\u20137.","journal-title":"J Reprod Med."},{"issue":"12","key":"1855_CR12","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/1097-0142(19871215)60:12<3049::AID-CNCR2820601232>3.0.CO;2-M","volume":"60","author":"SH Saul","year":"1987","unstructured":"Saul SH, Titelbaum DS, Gansler TS, Varello M, Burke DR, Atkinson BF, et al. The fibrolamellar variant of hepatocellular carcinoma. Its association with focal nodular hyperplasia. Cancer. 1987;60(12):3049\u201355.","journal-title":"Cancer."},{"issue":"3","key":"1855_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2559.1994.tb01328.x","volume":"25","author":"R Saxena","year":"1994","unstructured":"Saxena R, Humphreys S, Williams R, Portmann B. Nodular hyperplasia surrounding fibrolamellar carcinoma: a zone of arterialized liver parenchyma. Histopathology. 1994;25(3):275\u20138.","journal-title":"Histopathology."},{"issue":"4","key":"1855_CR14","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1093\/ajcp\/81.4.521","volume":"81","author":"FM Vecchio","year":"1984","unstructured":"Vecchio FM, Fabiano A, Ghirlanda G, Manna R, Massi G. Fibrolamellar carcinoma of the liver: the malignant counterpart of focal nodular hyperplasia with oncocytic change. American Journal of Clinical Pathology. 1984;81(4):521\u20136.","journal-title":"American Journal of Clinical Pathology."},{"issue":"6","key":"1855_CR15","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/1097-0142(19800915)46:6<1448::AID-CNCR2820460626>3.0.CO;2-J","volume":"46","author":"MM Berman","year":"1980","unstructured":"Berman MM, Libbey NP, Foster JH. Hepatocellular carcinoma. Polygonal cell type with fibrous stroma--an atypical variant with a favorable prognosis. Cancer. 1980;46(6):1448\u201355.","journal-title":"Cancer."},{"issue":"3","key":"1855_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/PAP.0b013e3180504913","volume":"14","author":"M Torbenson","year":"2007","unstructured":"Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol. 2007;14(3):217\u201323.","journal-title":"Adv Anat Pathol."},{"issue":"2","key":"1855_CR17","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.gtc.2017.01.009","volume":"46","author":"MS Torbenson","year":"2017","unstructured":"Torbenson MS. Morphologic subtypes of hepatocellular carcinoma. gastroenterology clinics of North America. 2017;46(2):365\u201391.","journal-title":"gastroenterology clinics of North America"},{"issue":"2","key":"1855_CR18","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1148\/radiology.213.2.r99nv31352","volume":"213","author":"T Ichikawa","year":"1999","unstructured":"Ichikawa T, Federle MP, Grazioli L, Madariaga J, Nalesnik M, Marsh W. Fibrolamellar hepatocellular carcinoma: imaging and pathologic findings in 31 recent cases. Radiology. 1999;213(2):352\u201361.","journal-title":"Radiology."},{"issue":"3","key":"1855_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1148\/radiology.157.3.2997835","volume":"157","author":"AC Friedman","year":"1985","unstructured":"Friedman AC, Lichtenstein JE, Goodman Z, Fishman EK, Siegelman SS, Dachman AH. Fibrolamellar hepatocellular carcinoma. Radiology. 1985;157(3):583\u20137.","journal-title":"Radiology."},{"issue":"5","key":"1855_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.21037\/cco.2018.08.08","volume":"7","author":"VA Chaudhari","year":"2018","unstructured":"Chaudhari VA, Khobragade K, Bhandare M, Shrikhande SV. Management of fibrolamellar hepatocellular carcinoma. Chin Clin Oncol. 2018;7(5):51.","journal-title":"Chin Clin Oncol."},{"issue":"4","key":"1855_CR21","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/hep.510260412","volume":"26","author":"AD Pinna","year":"1997","unstructured":"Pinna AD, Iwatsuki S, Lee RG, Todo S, Madariaga JR, Marsh JW, et al. Treatment of fibrolamellar hepatoma with subtotal hepatectomy or transplantation. Hepatology. 1997;26(4):877\u201383.","journal-title":"Hepatology."},{"issue":"14","key":"1855_CR22","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.3748\/wjg.v25.i14.1653","volume":"25","author":"T El Jabbour","year":"2019","unstructured":"El Jabbour T, Lagana SM, Lee H. Update on hepatocellular carcinoma: pathologists\u2019 review. World J Gastroenterol. 2019;25(14):1653\u201365.","journal-title":"World J Gastroenterol."},{"issue":"6","key":"1855_CR23","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/modpathol.2015.4","volume":"28","author":"RP Graham","year":"2015","unstructured":"Graham RP, Jin L, Knutson DL, Kloft-Nelson SM, Greipp PT, Waldburger N, et al. DNAJB1-PRKACA is specific for fibrolamellar carcinoma. Mod Pathol. 2015;28(6):822\u20139.","journal-title":"Mod Pathol."},{"issue":"6174","key":"1855_CR24","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.1249484","volume":"343","author":"JN Honeyman","year":"2014","unstructured":"Honeyman JN, Simon EP, Robine N, Chiaroni-Clarke R, Darcy DG, Lim II, et al. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014;343(6174):1010\u20134.","journal-title":"Science."},{"issue":"6","key":"1855_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/cncr.21703","volume":"106","author":"F Stipa","year":"2006","unstructured":"Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D\u2019Angelica M, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106(6):1331\u20138.","journal-title":"Cancer."},{"issue":"2","key":"1855_CR26","first-page":"49","volume":"7","author":"B Njei","year":"2014","unstructured":"Njei B, Konjeti VR, Ditah I. Prognosis of patients with fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis. Gastrointest Cancer Res. 2014;7(2):49\u201354.","journal-title":"Gastrointest Cancer Res."},{"key":"1855_CR27","first-page":"743790","volume":"2012","author":"M Torbenson","year":"2012","unstructured":"Torbenson M. Fibrolamellar carcinoma: 2012 update. Scientifica (Cairo). 2012;2012:743790.","journal-title":"Scientifica (Cairo)"},{"key":"1855_CR28","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. Jama. 2013;310(20):2191-4.","DOI":"10.1001\/jama.2013.281053"},{"issue":"2","key":"1855_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/BF03033723","volume":"8","author":"J Arista-Nasr","year":"2002","unstructured":"Arista-Nasr J, Gutierrez-Villalobos L, Nuncio J, Maldonaldo H, Bornstein-Quevedo L. Fibrolamellar hepatocellular carcinoma in mexican patients. Pathol Oncol Res. 2002;8(2):133\u20137.","journal-title":"Pathol Oncol Res."},{"issue":"20","key":"1855_CR30","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1002\/cncr.27520","volume":"118","author":"GG Malouf","year":"2012","unstructured":"Malouf GG, Brugieres L, Le Deley MC, Faivre S, Fabre M, Paradis V, et al. Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection. Cancer. 2012;118(20):4981\u201390.","journal-title":"Cancer."},{"issue":"10","key":"1855_CR31","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3390\/cancers10100380","volume":"10","author":"NB Abdol Razak","year":"2018","unstructured":"Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;10(10):380.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"1855_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1055\/s-0039-1697682","volume":"45","author":"B Bikdeli","year":"2019","unstructured":"Bikdeli B, Jimenez D, Garcia-Tsao G, Barba R, Font C, Diaz-Pedroche MDC, et al. Venous thromboembolism in patients with liver cirrhosis: findings from the RIETE (Registro Informatizado de la Enfermedad TromboEmbolica) registry. Semin Thromb Hemost. 2019;45(8):793\u2013801.","journal-title":"Semin Thromb Hemost."},{"issue":"9","key":"1855_CR33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.cgh.2010.05.014","volume":"8","author":"H Wu","year":"2010","unstructured":"Wu H, Nguyen GC. Liver cirrhosis is associated with venous thromboembolism among hospitalized patients in a nationwide US study. Clin Gastroenterol Hepatol. 2010;8(9):800\u20135.","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"17","key":"1855_CR34","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.3748\/wjg.v10.i17.2472","volume":"10","author":"SJ Hwang","year":"2004","unstructured":"Hwang SJ, Luo JC, Li CP, Chu CW, Wu JC, Lai CR, et al. Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol. 2004;10(17):2472\u20137.","journal-title":"World J Gastroenterol."},{"issue":"3","key":"1855_CR35","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/hep.24811","volume":"55","author":"SK Asrani","year":"2012","unstructured":"Asrani SK, LaRusso NF. Fibrolamellar hepatocellular carcinoma presenting with Budd-Chiari syndrome, right atrial thrombus, and pulmonary emboli. Hepatology. 2012;55(3):977\u20138.","journal-title":"Hepatology."},{"issue":"2","key":"1855_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.4103\/0973-1482.139537","volume":"11","author":"M Bhagat","year":"2015","unstructured":"Bhagat M, Kembhavi S, Qureshi SS. Fibrolamellar hepatocellular carcinoma with extensive vascular thrombosis. J Cancer Res Ther. 2015;11(2):493\u20134.","journal-title":"J Cancer Res Ther."},{"issue":"3","key":"1855_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.21037\/jgo.2019.01.28","volume":"10","author":"J Cho","year":"2019","unstructured":"Cho J, Chen JCY, Paludo J, Conboy EE, Lanpher BC, Alberts SR, et al. Hyperammonemic encephalopathy in a patient with fibrolamellar hepatocellular carcinoma: case report and literature review. J Gastrointest Oncol. 2019;10(3):582\u20138.","journal-title":"J Gastrointest Oncol."},{"key":"1855_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.12659\/AJCR.901682","volume":"18","author":"RC Surjan","year":"2017","unstructured":"Surjan RC, Dos Santos ES, Basseres T, Makdissi FF, Machado MA. A proposed physiopathological pathway to hyperammonemic encephalopathy in a non-cirrhotic patient with fibrolamellar hepatocellular carcinoma without ornithine transcarbamylase (OTC) mutation. Am J Case Rep. 2017;18:234\u201341.","journal-title":"Am J Case Rep."},{"key":"1855_CR39","doi-asserted-by":"crossref","unstructured":"Thakral N, Simonetto DA. Hyperammonemic encephalopathy: an unusual presentation of fibrolamellar hepatocellular carcinoma. Clin Mol Hepatol. 2019.","DOI":"10.3350\/cmh.2018.0042"},{"key":"1855_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.6061\/clinics\/2015(03)10","volume":"70","author":"AL Chagas","year":"2015","unstructured":"Chagas AL, Kikuchi L, Herman P, Alencar RSSM, Tani CM, Diniz MA, et al. Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases. Clinics. 2015;70:207\u201313.","journal-title":"Clinics."},{"issue":"1","key":"1855_CR41","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jpedsurg.2014.10.039","volume":"50","author":"DG Darcy","year":"2015","unstructured":"Darcy DG, Malek MM, Kobos R, Klimstra DS, DeMatteo R, La Quaglia MP. Prognostic factors in fibrolamellar hepatocellular carcinoma in young people. J Pediatr Surg. 2015;50(1):153\u20136.","journal-title":"J Pediatr Surg."},{"issue":"3","key":"1855_CR42","doi-asserted-by":"publisher","first-page":"554","DOI":"10.21037\/jgo.2019.01.35","volume":"10","author":"S Chakrabarti","year":"2019","unstructured":"Chakrabarti S, Tella SH, Kommalapati A, Huffman BM, Yadav S, Riaz IB, et al. Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma. J Gastrointest Oncol. 2019;10(3):554\u201361.","journal-title":"J Gastrointest Oncol."},{"issue":"1","key":"1855_CR43","first-page":"3","volume":"6","author":"CS Ang","year":"2013","unstructured":"Ang CS, Kelley RK, Choti MA, Cosgrove DP, Chou JF, Klimstra D, et al. Clinicopathologic characteristics and survival outcomes of patients with fibrolamellar carcinoma: data from the fibrolamellar carcinoma consortium. Gastrointest Cancer Res. 2013;6(1):3\u20139.","journal-title":"Gastrointest Cancer Res."},{"issue":"5","key":"1855_CR44","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1007\/s00270-018-1903-6","volume":"41","author":"S Mafeld","year":"2018","unstructured":"Mafeld S, French J, Tiniakos D, Haugk B, Manas D, Littler P. Fibrolamellar hepatocellular carcinoma: treatment with yttrium-90 and subsequent surgical resection. Cardiovasc Intervent Radiol. 2018;41(5):816\u201320.","journal-title":"Cardiovasc Intervent Radiol."},{"issue":"2","key":"1855_CR45","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3109\/01443615.2011.621558","volume":"32","author":"V Benito","year":"2012","unstructured":"Benito V, Segura J, Martinez MS, Arencibia O, Lubrano A. Fibrolamellar hepatocellular carcinoma metastatic to the ovary. J Obstet Gynaecol. 2012;32(2):200\u20132.","journal-title":"J Obstet Gynaecol."},{"key":"1855_CR46","doi-asserted-by":"crossref","unstructured":"Ince V, Isik B, Ozdemir F, Ozgor D, Ara C, Yilmaz S. Living-donor liver transplant for fibrolamellar hepatocellular carcinoma with hilar lymph node metastasis: a case report. Exp Clin Transplant. 2018.","DOI":"10.6002\/ect.2017.0040"},{"issue":"1","key":"1855_CR47","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/hep.29853","volume":"68","author":"R Bill","year":"2018","unstructured":"Bill R, Montani M, Blum B, Dufour JF, Escher R, Buhlmann M. Favorable response to mammalian target of rapamycin inhibition in a young patient with unresectable fibrolamellar carcinoma of the liver. Hepatology. 2018;68(1):384\u20136.","journal-title":"Hepatology."},{"issue":"1","key":"1855_CR48","first-page":"187","volume":"58","author":"SH Ciurea","year":"2017","unstructured":"Ciurea SH, Matei E, Stanescu CS, Lupescu IG, Boros M, Herlea V, et al. Fibrolamellar hepatocellular carcinoma with ovarian metastasis - an unusual presentation. Rom J Morphol Embryol. 2017;58(1):187\u201392.","journal-title":"Rom J Morphol Embryol."},{"issue":"8","key":"1855_CR49","first-page":"494","volume":"108","author":"E Estrella Diez","year":"2016","unstructured":"Estrella Diez E, Alvarez Higueras FJ, Marin Zafra G, Bas Bernal A, Garre Sanchez C, Egea Valenzuela J, et al. Fibrolamellar hepatocellular carcinoma: a rare entity diagnosed by abdominal ultrasound. Rev Esp Enferm Dig. 2016;108(8):494\u20135.","journal-title":"Rev Esp Enferm Dig."},{"issue":"1","key":"1855_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000497464","volume":"35","author":"U Bauer","year":"2019","unstructured":"Bauer U, Mogler C, Braren RF, Algul H, Schmid RM, Ehmer U. Progression after immunotherapy for fibrolamellar carcinoma. Visc Med. 2019;35(1):39\u201342.","journal-title":"Visc Med."},{"issue":"6","key":"1855_CR51","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1016\/j.jpainsymman.2015.03.007","volume":"49","author":"HU Bender","year":"2015","unstructured":"Bender HU, Staudigl M, Schmid I, Fuhrer M. Treatment of paraneoplastic hyperammonemia in fibrolamellar hepatocellular carcinoma with oral sodium phenylbutyrate. J Pain Symptom Manage. 2015;49(6):e8\u201310.","journal-title":"J Pain Symptom Manage."},{"issue":"1","key":"1855_CR52","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/ccr3.34","volume":"2","author":"YP Vandewynckel","year":"2014","unstructured":"Vandewynckel YP, Geerts A, Verhelst X, Van Vlierberghe H. Cerebellar stroke in a low cardiovascular risk patient associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma. Clin Case Rep. 2014;2(1):4\u20136.","journal-title":"Clin Case Rep."},{"key":"1855_CR53","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/8904_2014_318","volume":"16","author":"RA Sulaiman","year":"2014","unstructured":"Sulaiman RA, Geberhiwot T. Fibrolamellar hepatocellular carcinoma mimicking ornithine transcarbamylase deficiency. JIMD Rep. 2014;16:47\u201350.","journal-title":"JIMD Rep."},{"issue":"10","key":"1855_CR54","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.dld.2014.05.010","volume":"46","author":"M Chiarelli","year":"2014","unstructured":"Chiarelli M, De Simone M, Guttadauro A, Cioffi U. Fibrolamellar carcinoma in a 62\u2009year-old patient with human immunodeficiency virus infection. Dig Liver Dis. 2014;46(10):959.","journal-title":"Dig Liver Dis."},{"issue":"5","key":"1855_CR55","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1097\/MPH.0000000000000137","volume":"36","author":"A Okur","year":"2014","unstructured":"Okur A, Eser EP, Yilmaz G, Dalgic A, Akdemir UO, Oguz A, et al. Successful multimodal treatment for aggressive metastatic and recurrent fibrolamellar hepatocellular carcinoma in a child. J Pediatr Hematol Oncol. 2014;36(5):e328\u201332.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"5","key":"1855_CR56","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1111\/his.12312","volume":"64","author":"Y Zen","year":"2014","unstructured":"Zen Y, Vara R, Portmann B, Hadzic N. Childhood hepatocellular carcinoma: a clinicopathological study of 12 cases with special reference to EpCAM. Histopathology. 2014;64(5):671\u201382.","journal-title":"Histopathology."},{"key":"1855_CR57","first-page":"679565","volume":"2013","author":"V Minutolo","year":"2013","unstructured":"Minutolo V, Licciardello A, Arena M, Minutolo O, Lanteri R, Arena G. Surgical resection of ruptured fibrolamellar hepatocellular carcinoma. Case Rep Surg. 2013;2013:679565.","journal-title":"Case Rep Surg."},{"issue":"10","key":"1855_CR58","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1007\/s11604-013-0233-5","volume":"31","author":"AM De Gaetano","year":"2013","unstructured":"De Gaetano AM, Nure E, Grossi U, Frongillo F, Russo R, Vecchio FM, et al. Fibrolamellar hepatocellular carcinoma with biliary tumor thrombus: an unreported association. Jpn J Radiol. 2013;31(10):706\u201312.","journal-title":"Jpn J Radiol."},{"issue":"5","key":"1855_CR59","first-page":"425","volume":"72","author":"C Berger","year":"2012","unstructured":"Berger C, Dimant P, Hermida L, Paulin F, Pereyra M, Tejo M. Hyperammonemic encephalopathy and fibrolamellar hepatocellular carcinoma. Medicina (B Aires). 2012;72(5):425\u20137.","journal-title":"Medicina (B Aires)"},{"issue":"5","key":"1855_CR60","first-page":"529","volume":"13","author":"M Wojcicki","year":"2012","unstructured":"Wojcicki M, Lubikowski J, Post M, Chmurowicz T, Wiechowska-Kozlowska A, Krawczyk M. Aggressive surgical management of recurrent lymph node and pancreatic head metastases of resected fibrolamellar hepatocellular carcinoma: a case report. Jop. 2012;13(5):529\u201332.","journal-title":"Jop."},{"issue":"1","key":"1855_CR61","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000338242","volume":"5","author":"P Gras","year":"2012","unstructured":"Gras P, Truant S, Boige V, Ladrat L, Rougier P, Pruvot FR, et al. Prolonged complete response after GEMOX chemotherapy in a patient with advanced fibrolamellar hepatocellular carcinoma. Case Rep Oncol. 2012;5(1):169\u201372.","journal-title":"Case Rep Oncol."},{"issue":"1","key":"1855_CR62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.clinre.2011.09.008","volume":"36","author":"S Koudah","year":"2012","unstructured":"Koudah S, El Mouhadi S, Arrive L. Fibrolamellar hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2012;36(1):5\u20136.","journal-title":"Clin Res Hepatol Gastroenterol."},{"issue":"9797","key":"1855_CR63","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/S0140-6736(11)61022-2","volume":"378","author":"V Brunel","year":"2011","unstructured":"Brunel V, Cauliez B, Lacaze L, Riachi G, Gargala G, Francois A, et al. Liver mass in a young adult. Lancet. 2011;378(9797):1196.","journal-title":"Lancet."},{"issue":"Suppl 2","key":"1855_CR64","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/2047-783X-15-S2-95","volume":"15","author":"RM Mroz","year":"2010","unstructured":"Mroz RM, Korniluk M, Swidzinska E, Dzieciol J, Czaban J, Panek B, et al. Lung mass in a 28-year-old male: a case report of a rare tumor. Eur J Med Res. 2010;15(Suppl 2):95\u20137.","journal-title":"Eur J Med Res."},{"issue":"1","key":"1855_CR65","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12029-009-9094-7","volume":"41","author":"I Terzis","year":"2010","unstructured":"Terzis I, Haritanti A, Economou I. Fibrolamellar hepatocellular carcinoma: a case report with distinct radiological features. J Gastrointest Cancer. 2010;41(1):2\u20135.","journal-title":"J Gastrointest Cancer."},{"issue":"4","key":"1855_CR66","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1634\/theoncologist.2015-0267","volume":"21","author":"CI Chapuy","year":"2016","unstructured":"Chapuy CI, Sahai I, Sharma R, Zhu AX, Kozyreva ON. Hyperammonemic encephalopathy associated with fibrolamellar hepatocellular carcinoma: case report, literature review, and proposed treatment algorithm. Oncologist. 2016;21(4):514\u201320.","journal-title":"Oncologist."},{"issue":"6","key":"1855_CR67","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1097\/MAJ.0b013e3181bccfb4","volume":"338","author":"S Sethi","year":"2009","unstructured":"Sethi S, Tageja N, Singh J, Arabi H, Dave M, Badheka A, et al. Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma. Am J Med Sci. 2009;338(6):522\u20134.","journal-title":"Am J Med Sci."},{"issue":"5","key":"1855_CR68","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1053\/j.gastro.2012.07.002","volume":"143","author":"JG Hashash","year":"2012","unstructured":"Hashash JG, Thudi K, Malik SM. An 18-year-old woman with a 15-cm liver mass and an ammonia level of 342. Gastroenterology. 2012;143(5):1157\u2013402.","journal-title":"Gastroenterology."},{"issue":"4","key":"1855_CR69","doi-asserted-by":"publisher","DOI":"10.14309\/crj.2016.79","volume":"3","author":"AE Alsina","year":"2016","unstructured":"Alsina AE, Franco E, Nakshabandi A, Albers C, Kemmer N, Berry AC, et al. Successful liver transplantation for hyperammonemic fibrolamellar hepatocellular carcinoma. ACG Case Rep J. 2016;3(4):e106.","journal-title":"ACG Case Rep J."},{"issue":"5","key":"1855_CR70","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/SMJ.0b013e31816bf5cc","volume":"101","author":"JS Chan","year":"2008","unstructured":"Chan JS, Harding CO, Blanke CD. Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency. South Med J. 2008;101(5):543\u20135.","journal-title":"South Med J."},{"key":"1855_CR71","doi-asserted-by":"publisher","first-page":"7521986","DOI":"10.1155\/2018\/7521986","volume":"2018","author":"O Suarez","year":"2018","unstructured":"Suarez O, Perez M, Garzon M, Daza R, Hernandez G, Salinas C, et al. Fibrolamellar hepatocellular carcinoma and noncirrhotic hyperammonemic encephalopathy. Case Reports Hepatol. 2018;2018:7521986.","journal-title":"Case Reports Hepatol."},{"issue":"2","key":"1855_CR72","first-page":"115","volume":"23","author":"JJ Khoo","year":"2001","unstructured":"Khoo JJ, Clouston A. Fibrolamellar hepatocellular carcinoma: a case report. Malays J Pathol. 2001;23(2):115\u20138.","journal-title":"Malays J Pathol."},{"issue":"5","key":"1855_CR73","first-page":"237","volume":"88","author":"J Marrannes","year":"2005","unstructured":"Marrannes J, Gryspeerdt S, Haspeslagh M, van Holsbeeck B, Baekelandt M, Lefere P. Fibrolamellar hepatocellular carcinoma in a 65-year-old woman: CT features. JBR-BTR. 2005;88(5):237\u201340.","journal-title":"JBR-BTR."},{"issue":"3-4","key":"1855_CR74","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1159\/000200995","volume":"53","author":"R Lamberts","year":"1992","unstructured":"Lamberts R, Nitsche R, de Vivie RE, Peitsch W, Schauer A, Schuster R, et al. Budd-Chiari syndrome as the primary manifestation of a fibrolamellar hepatocellular carcinoma. Digestion. 1992;53(3-4):200\u20139.","journal-title":"Digestion."},{"issue":"10","key":"1855_CR75","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1007\/BF02093600","volume":"41","author":"S Saab","year":"1996","unstructured":"Saab S, Yao F. Fibrolamellar hepatocellular carcinoma. Case reports and a review of the literature. Dig Dis Sci. 1996;41(10):1981\u20135.","journal-title":"Dig Dis Sci."},{"issue":"8","key":"1855_CR76","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/dc.20498","volume":"34","author":"D Mansouri","year":"2006","unstructured":"Mansouri D, Van Nhieu JT, Couanet D, Terrier-Lacombe MJ, Brugieres L, Cherqui D, et al. Fibrolamellar hepatocellular carcinoma: a case report with cytological features in a sixteen-year-old girl. Diagn Cytopathol. 2006;34(8):568\u201371.","journal-title":"Diagn Cytopathol."},{"issue":"5","key":"1855_CR77","doi-asserted-by":"publisher","first-page":"e195","DOI":"10.1097\/MPH.0b013e3182011676","volume":"33","author":"K Muramori","year":"2011","unstructured":"Muramori K, Taguchi S, Taguchi T, Kohashi K, Furuya K, Tokuda K, et al. High aromatase activity and overexpression of epidermal growth factor receptor in fibrolamellar hepatocellular carcinoma in a child. J Pediatr Hematol Oncol. 2011;33(5):e195\u20137.","journal-title":"J Pediatr Hematol Oncol."},{"issue":"2","key":"1855_CR78","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1148\/rg.282075153","volume":"28","author":"MT Smith","year":"2008","unstructured":"Smith MT, Blatt ER, Jedlicka P, Strain JD, Fenton LZ. Best cases from the AFIP: fibrolamellar hepatocellular carcinoma. Radiographics. 2008;28(2):609\u201313.","journal-title":"Radiographics."},{"issue":"6","key":"1855_CR79","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1177\/000992289803700606","volume":"37","author":"ES Sher","year":"1998","unstructured":"Sher ES, Migeon CJ, Berkovitz GD. Evaluation of boys with marked breast development at puberty. Clin Pediatr (Phila). 1998;37(6):367\u201371.","journal-title":"Clin Pediatr (Phila)."},{"issue":"2","key":"1855_CR80","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/(SICI)1096-911X(199702)28:2<136::AID-MPO8>3.0.CO;2-L","volume":"28","author":"MA Hany","year":"1997","unstructured":"Hany MA, Betts DR, Schmugge M, Schonle E, Niggli FK, Zachmann M, et al. A childhood fibrolamellar hepatocellular carcinoma with increased aromatase activity and a near triploid karyotype. Med Pediatr Oncol. 1997;28(2):136\u20138.","journal-title":"Med Pediatr Oncol."},{"issue":"3","key":"1855_CR81","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1542\/peds.82.3.379","volume":"82","author":"JJ McCloskey","year":"1988","unstructured":"McCloskey JJ, Germain-Lee EL, Perman JA, Plotnick LP, Janoski AH. Gynecomastia as a presenting sign of fibrolamellar carcinoma of the liver. Pediatrics. 1988;82(3):379\u201382.","journal-title":"Pediatrics."},{"issue":"5","key":"1855_CR82","first-page":"1797","volume":"83","author":"VR Agarwal","year":"1998","unstructured":"Agarwal VR, Takayama K, Van Wyk JJ, Sasano H, Simpson ER, Bulun SE. Molecular basis of severe gynecomastia associated with aromatase expression in a fibrolamellar hepatocellular carcinoma. J Clin Endocrinol Metab. 1998;83(5):1797\u2013800.","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"1855_CR83","doi-asserted-by":"publisher","first-page":"197","DOI":"10.4103\/0256-4947.76409","volume":"31","author":"K Al-Matham","year":"2011","unstructured":"Al-Matham K, Alabed I, Zaidi SZ, Qushmaq KA. Cold agglutinin disease in fibrolamellar hepatocellular carcinoma: a rare association with a rare cancer variant. Ann Saudi Med. 2011;31(2):197\u2013200.","journal-title":"Ann Saudi Med."}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-020-01855-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-020-01855-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,23]],"date-time":"2022-10-23T11:12:41Z","timestamp":1666523561000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-020-01855-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,12]]},"references-count":83,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1855"],"URL":"https:\/\/doi.org\/10.1186\/s12957-020-01855-2","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,12]]},"assertion":[{"value":"26 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}